Andy Smith

Dr. Andy Smith is an Analyst at Equity Development Ltd.
Dr. Smith joined Equity Development at the end of 2019 after nearly two years in the healthcare team at Edison and before that, as a senior principal in ICON’s Pricing & Market Access consultancy.
Prior to ICON he was chief investment officer at Mann Bioinvest and managed healthcare and biotech funds at AXA Framlington, SV Life Sciences, Schroders and 3i Group.
He is a scientist by training and worked for ICI and in the NHS.
Between working as a lecturer at Guy’s Medical School, he worked in R&D management at SmithKline Beecham, before moving to the strategic product development group in SB Pharmaceuticals to be a global product manager.
Dr. Smith completed his PhD with Glaxochem and also has an MBA from the University of Greenwich and the Master’s in Bio-business at Birkbeck, University of London.